Transplant Diagnostic Market is Projected to

Transplant Diagnostic Market is Projected to Expand at a Cumulative Annual Growth Rate (CAGR) of 6.6% From 2018 to 2026

The global transplant diagnostic market was valued at US$ 730.9 Mn in 2017 and is projected to expand at a cumulative annual growth rate (CAGR) of 6.6% from 2018 to 2026 according to a new report published by Transparency Market Research (TMR) titled “Transplant Diagnostic Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026” the report suggests that increase in number of cancer & blood disorder patients and rise in the demand for accurate and cost-effective transplant diagnostic systems is fueling the transplant diagnostic market between 2018 and 2026.

North America and Europe are projected to dominate the global market owing to the increase in demand for efficient and effective management of transplant diagnostic technique and high adoption rate of transplant of organs. The market in Asia Pacific is projected to expand at a prominent growth rate during the forecast period. Expansion of the market in Asia Pacific is attributed to the large base of hospital & transplant centers and research centers, rising number of geriatric population requiring kidney dialysis services, and increasing awareness regarding donation of organs among young generation in the region. The market for transplant diagnostic in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request a Sample of Transplant Diagnostic Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20225

• Technological assay in transplant diagnostic is expected to fuel global market

The global transplant diagnostic market is projected to be potentially driven by the technological assay offered by various transplant diagnostic companies. Transplant diagnostic provides a wide range of features and benefits such as identification of molecules that are expressed on the cells and are involved in the immune rejection of mismatched grafts and recognition of foreign HLA Class 2 antigens, which makes it more feasible for rapid results in transplantation technique. These features help physicians and nurses to streamline the transplantation activity required for the patients in order to maintain their daily workflow efficiently and effectively.

Key players offering transplant diagnostic are developing value-added features such as real-time PCR technology, PCR-enzyme-linked immunosorbent assay, along with imaging modules, thereby reducing the overall operating cost, which in turn improves the overall effectiveness and efficiency of diagnostic practices. Companies are focusing on the development of PCR-based products and expansion of their operations and increase in their market shares. For instance, in April 2016, Siemens and Thermo Fisher Scientific entered into a partnership, allowing Siemens to integrate Thermo Fisher Scientific's real-time PCR technology in its own technology. These value-added features and advanced assay offers rapid and sensitive detection limit, helping improve the overall duration and quality of diagnostics.